COVID-19 Post-Vaccination Observation

Active, not recruiting

• Conditions: Immune System Disorder; COVID-19 Vaccine Adverse Reaction; Immune System Diseases

• Registration Number: NCT06107348
• Lead Sponsor: Yang I. Pachankis, PhD

Brief Summary

The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis. The study continued to the third-dose full vaccination of the participant with the recombined COVID-19 vaccination and afterwards. The study completed until intervention.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-01
• Primary Completion: 2023-01-04
• Status Verified: 2023-10
• Study First Submitted: 2023-10-26
• Study First Submitted QC: 2023-10-26
• Last Update Submitted: 2023-10-26
• Study First Posted: 2023-10-30
• Last Update Posted: 2023-10-30
• Study Completion: 2023-12-24

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alpha Fetoprotein	7 months
Chemiluminescent Immunoassay for Human Immunodeficiency Virus	7 months
Mucin-16	7 months
Leukocytes	7 months
Carbohydrate Antigen 19-9	7 months
Cancer Antigen 15-3	7 months
Leukocyte Percentage	7 months
Carcinoembryonic Antigen	7 months
Prostate-Specific Antigen	7 months
Cholesterol	7 months

Trial Locations

Locations (1)

Residential Address; 🇨🇳 Chongqing, Chongqing, China